Compare Duke Energy Corp (DUK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Incyte Corporation — how do they compare? Duke Energy Corp trades at $116.65 (market cap $91.10B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Duke Energy Corp is far larger — about 4× Incyte Corporation's market cap, and Duke Energy Corp pays a 3.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Incyte Corporation for 33 Days on average.
| DUK | INCY | |
|---|---|---|
Market Cap | $91.10B | $22.85B |
Volume | 4,199,050 | 1,927,029 |
Sector | Utilities | Health |
52-Week High | $133.46 | $129.93 |
52-Week Low | $113.23 | $83.80 |
Typical Hold Time | 74 Days | 33 Days |
Enterprise Value | $183.61B | $18.35B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.55, up 0.91% today, with a bullish technical signal despite mixed moving averages. The company shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding the $1.30 estimate. Revenue grew to $32.24B in 2025, and net income margin improved to 15.78%. Recent news highlights dividend declarations and data center growth opportunities, though rising Treasury yields pose a headwind for utility stocks.
DUK offers a stable dividend and benefits from data center demand, but high debt levels and interest rate sensitivity present risks. Analyst consensus is a Buy with a $134.44 price target, implying 15% upside. The stock's valuation is reasonable with a P/E of 17.6, supporting a cautious bullish outlook amid macroeconomic pressures.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
